Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 23 Mar 2005 |
| Erkki Etola re-elected Vice Chairman of Orion?s Board of Directors | 23 Mar 2005 |
| CEO Jukka Viinanen at Orion?s AGM: Good start for 2005. Full-year outlook unchanged | 22 Mar 2005 |
| Amendment to Notes of Orion Corporation 2004 Financial Statements | 9 Mar 2005 |
| Orion Group 2004 Financial Statements | 14 Feb 2005 |